{
  "id": 19364943,
  "title": "Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition",
  "url": "https://urgent.news/2026/11/10/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T16:52:57.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/"
  },
  "original_language": "en",
  "account": "Argenx has agreed to acquire Unnatural Products (UNP) for up to $1.15 billion, expanding its immunology capabilities. The deal is designed to combine UNP's macrocyclic peptide discovery platform with Argenx's immunology innovation expertise, enabling the development of oral or long-acting treatments for serious immune-mediated diseases. This acquisition transforms Argenx from a minority stakeholder in UNP to the sole owner of its shares. Argenx aims to diversify its pipeline beyond its antibody-based portfolio, which includes blockbuster drugs Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo. The acquisition marks Argenx's next chapter, with CEO Karen Massey emphasizing the company's ambition to be the leading immunology innovation company.",
  "summary": "The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}